| Natural Progesterone for the Treatment of Recurrent Glioblastoma (NCT05091866) | Emory University | 2022-04-11 |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (NCT05095376) | NRG Oncology | 2022-03-28 |
| Study of Pembrolizumab and M032 (NSC 733972) (NCT05084430) | University of Alabama at Birmingham | 2022-02-25 |
| Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (NCT04817254) | National Cancer Institute (NCI) | 2021-12-08 |
| Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma (NCT04397679) | Barbara Ann Karmanos Cancer Institute | 2021-08-12 |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma (NCT04528680) | Northwestern University | 2020-10-29 |
| Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (NCT04555577) | M.D. Anderson Cancer Center | 2020-09-20 |
| Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (NCT04396860) | National Cancer Institute (NCI) | 2020-09-01 |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (NCT04216329) | National Cancer Institute (NCI) | 2020-07-07 |
| Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma (NCT04091503) | Center Trials & Treatment Europe | 2019-12-20 |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma (NCT03014804) | Jonsson Comprehensive Cancer Center | 2019-12-01 |
| Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (NCT03973918) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-07-29 |
| Sunitinib in Sarcomas of the Central Nervous System (NCT03641326) | National Cancer Institute (NCI) | 2019-02-21 |
| Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma (NCT03746080) | Lawrence D Recht | 2018-12-04 |
| Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma (NCT03452930) | M.D. Anderson Cancer Center | 2018-08-13 |
| Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma (NCT03275558) | Center Trials & Treatment | 2018-07-17 |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (NCT03107780) | National Cancer Institute (NCI) | 2018-07-09 |
| Multi-site Validation and Application of a Consensus DSC-MRI Protocol (NCT03401866) | St. Joseph's Hospital and Medical Center, Phoenix | 2018-02-01 |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma (NCT03197506) | Mayo Clinic | 2018-01-15 |
| Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (NCT03043391) | Istari Oncology, Inc. | 2017-11-07 |
| DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma (NCT03115333) | ECOG-ACRIN Cancer Research Group | 2017-07-25 |
| Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (NCT03174197) | M.D. Anderson Cancer Center | 2017-06-30 |
| NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery (NCT03020017) | Northwestern University | 2017-05-25 |
| Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (NCT02743078) | RTOG Foundation, Inc. | 2017-05-09 |
| EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (NCT02664363) | Daniel Landi | 2017-02-01 |
| BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab (NCT03020602) | Seema Nagpal | 2017-01-04 |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (NCT02101905) | National Cancer Institute (NCI) | 2016-11-07 |
| Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (NCT02798406) | DNAtrix, Inc. | 2016-10-06 |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (NCT02709226) | National Cancer Institute (NCI) | 2016-06-15 |
| Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma (NCT02661282) | M.D. Anderson Cancer Center | 2016-06-01 |
| Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab (NCT01931098) | National Cancer Institute (NCI) | 2015-12-10 |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors (NCT02502708) | NewLink Genetics Corporation | 2015-10-01 |
| INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme (NCT02386826) | SCRI Development Innovations, LLC | 2015-09-22 |
| SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (NCT02455557) | Roswell Park Cancer Institute | 2015-05-04 |
| Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (NCT02311920) | National Cancer Institute (NCI) | 2015-04-16 |
| A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (NCT02573324) | AbbVie | 2015-01-04 |
| Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT02152982) | National Cancer Institute (NCI) | 2014-12-15 |
| Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma (NCT03843814) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-08-01 |
| Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (NCT02133183) | National Cancer Institute (NCI) | 2014-07-02 |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma (NCT02168270) | University of Nebraska | 2014-06-16 |
| ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (NCT01903330) | Epitopoietic Research Corporation | 2014-03-01 |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors (NCT02052648) | NewLink Genetics Corporation | 2014-03-01 |
| Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (NCT01957956) | Mayo Clinic | 2013-11-11 |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (NCT01922076) | National Cancer Institute (NCI) | 2013-09-03 |
| p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors (NCT01975116) | Pediatric Brain Tumor Consortium | 2013-08-01 |
| BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (NCT01856933) | Heinrich Elinzano, MD | 2013-05-01 |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (NCT01836549) | Pediatric Brain Tumor Consortium | 2013-03-01 |
| Bevacizumab Beyond Progression (BBP) (NCT01740258) | Duke University | 2013-01-01 |
| Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas (NCT01721577) | Rush University Medical Center | 2012-12-01 |
| Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (NCT01250470) | Roswell Park Cancer Institute | 2012-09-05 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (NCT01609790) | National Cancer Institute (NCI) | 2012-06-04 |
| CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII (NCT01454596) | National Cancer Institute (NCI) | 2012-05-16 |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas (NCT01514201) | National Cancer Institute (NCI) | 2012-02-01 |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (NCT01498328) | Celldex Therapeutics | 2011-12-01 |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (NCT01480479) | Celldex Therapeutics | 2011-11-01 |
| Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy (NCT01430351) | M.D. Anderson Cancer Center | 2011-09-14 |
| A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma (NCT01227434) | University of California, San Francisco | 2010-09-01 |
| Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (NCT01189266) | National Cancer Institute (NCI) | 2010-08-09 |
| AMG 102 and Avastin for Recurrent Malignant Glioma (NCT01113398) | Katy Peters | 2010-08-01 |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 (NCT01082926) | City of Hope Medical Center | 2010-05-01 |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma (NCT01149850) | Jonsson Comprehensive Cancer Center | 2010-04-28 |
| Radiosurgery Plus Bevacizumab in Glioblastoma (NCT01086345) | Case Comprehensive Cancer Center | 2010-02-01 |
| Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma (NCT01004874) | Duke University | 2009-12-30 |
| Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma (NCT01124539) | Arno Therapeutics | 2009-12-01 |
| Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme (NCT00979017) | Katy Peters | 2009-11-01 |
| Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma (NCT00879437) | Baylor College of Medicine | 2009-09-01 |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma (NCT00960492) | Exelixis | 2009-09-01 |
| A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas (NCT00995007) | National Cancer Institute (NCI) | 2009-09-01 |
| Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma (NCT00734864) | Annick Desjardins | 2009-06-01 |
| Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma (NCT00884741) | National Cancer Institute (NCI) | 2009-04-15 |
| Sorafenib in Newly Diagnosed High Grade Glioma (NCT00884416) | University Hospital, Geneva | 2009-03-01 |
| O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (NCT00669669) | Fred Hutchinson Cancer Center | 2009-02-25 |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma (NCT01095094) | Case Comprehensive Cancer Center | 2009-01-01 |
| Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma (NCT00734526) | M.D. Anderson Cancer Center | 2008-12-18 |
| Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma (NCT00936052) | Neurological Surgery, P.C. | 2008-12-01 |
| Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma (NCT02599090) | M.D. Anderson Cancer Center | 2008-12-01 |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) (NCT00735436) | Duke University | 2008-12-01 |
| Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors (NCT00667394) | National Cancer Institute (NCI) | 2008-04-01 |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan (NCT00613028) | Duke University | 2008-04-01 |
| Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas (NCT00613223) | Annick Desjardins | 2008-02-01 |
| Ph I Dasatinib + Erlotinib in Recurrent MG (NCT00609999) | Duke University | 2008-01-01 |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma (NCT00613054) | Annick Desjardins | 2007-11-01 |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma (NCT00525525) | University of California, San Francisco | 2007-09-01 |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas (NCT00612339) | Duke University | 2007-08-01 |
| Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas (NCT00597402) | Duke University | 2007-07-01 |
| Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors (NCT00441142) | Patrick Y. Wen, MD | 2007-05-25 |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG (NCT00612430) | Duke University | 2007-03-01 |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) (NCT00671970) | Duke University | 2007-02-01 |
| Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients (NCT00402116) | Eli Lilly and Company | 2006-09-01 |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma (NCT00365222) | H. Lee Moffitt Cancer Center and Research Institute | 2006-07-01 |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) (NCT00615927) | Duke University | 2006-02-01 |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas (NCT00612651) | Duke University | 2005-10-01 |
| Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00165477) | Dana-Farber Cancer Institute | 2005-09-01 |
| Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG (NCT00613132) | Annick Desjardins | 2005-05-01 |
| Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma (NCT00354913) | Duke University | 2005-05-01 |
| GW572016 to Treat Recurrent Malignant Brain Tumors (NCT00107003) | National Cancer Institute (NCI) | 2005-03-30 |
| Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas (NCT00100802) | Children's Oncology Group | 2005-03-21 |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM (NCT00612989) | Duke University | 2005-02-01 |
| Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas (NCT00612638) | Duke University | 2005-01-01 |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma (NCT00114309) | TransMolecular | 2004-11-01 |